HVEM, LIGHT & BTLA: New Immunotherapy Target
The checkpoint receptors HVEM , LIGHT , CD160 , and BTLA are part of a complex network of overlapping receptor interactions that function in both immune stimulation and suppression 1 , 2 . This regulatory function has made them therapeutic targets for treatment of cancer, autoimmune diseases and allergies, and for improved methods of organ transplants. While presenting opportunities for...
